# Phase I Trial of VS-6766 Alone and in Combination With Everolimus

> **NCT02407509** · PHASE1 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 104 (estimated)

## Conditions studied

- Solid Tumours
- Multiple Myeloma
- Lung Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** VS-6766
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02407509
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-17
- **Primary completion:** 2025-10-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407509, "Phase I Trial of VS-6766 Alone and in Combination With Everolimus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02407509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*